Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) rose 0.7% during trading on Tuesday. The stock traded as high as C$8.77 and last traded at C$8.64. Approximately 314,186 shares were traded during trading, an increase of 4,140% from the average session volume of 7,410 shares. The stock had previously closed at C$8.58.
Eupraxia Pharmaceuticals Stock Down 5.1%
The business’s 50 day moving average price is C$7.09 and its two-hundred day moving average price is C$7.02.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
